CD30 expression in cutaneous B-cell lymphomas.
B-cell lymphoma
CD30
cutaneous
Journal
Journal of cutaneous pathology
ISSN: 1600-0560
Titre abrégé: J Cutan Pathol
Pays: United States
ID NLM: 0425124
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
revised:
15
04
2023
received:
04
12
2022
accepted:
22
05
2023
medline:
14
8
2023
pubmed:
9
6
2023
entrez:
8
6
2023
Statut:
ppublish
Résumé
CD30 expression has been infrequently described in cutaneous B-cell lymphomas (CBCLs). We examined CD30 expression in reactive lymphoid hyperplasia (RLH) and CBCL and correlated expression with clinicopathologic features. CD30 was examined in 82 CBCL patients and 10 RLH patients that had been evaluated in our cutaneous lymphoma clinics. The CBCL patients included: primary cutaneous follicle center lymphoma (PCFCL), Grade 1/2 systemic/nodal follicular lymphoma (SFL); primary cutaneous marginal zone lymphoma/lymphoproliferative disorder (PCMZL/LPD); systemic marginal zone lymphoma (SMZL); primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT); and extracutaneous/systemic diffuse large B-cell lymphoma (eDLBCL). We scored CD30 expression for intensity and extent and related CD30 expression to age at first diagnosis, sex, site of biopsy, clinical appearance, extracutaneous involvement, multiple cutaneous lesions, B-symptoms, lymphadenopathy, positive positron emission tomography/computed tomography (PET/CT), elevated lactate dehydrogenase (LDH), and positive bone marrow biopsy. CD30 expression was identified in 35% of CBCL, ranging from few, weak, scattered cells to strong and diffuse expression. It was most common in PCFCL and was not expressed in PCDLBCL-LT. Rare PCFCL expressed strong, diffuse CD30. Some cases of PCMZL/LPD, SMZL, FL, and RLH showed scattered, strongly positive cells. CD30 expression in CBCL was associated with favorable clinical features: younger age, negative PET/CT, and an LDH within normal limits. CD30 may be expressed in CBCL, possibly causing diagnostic confusion. CD30 expression was most commonly identified in PCFCL and is associated with favorable clinical features. In cases with strong and diffuse expression, CD30 could be a therapeutic target.
Substances chimiques
Ki-1 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
819-827Subventions
Organisme : University of Michigan Department of Pathology
Informations de copyright
© 2023 The Authors. Journal of Cutaneous Pathology published by John Wiley & Sons Ltd.
Références
Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703-1714.
Willemze R. Primary cutaneous lymphoma: the 2018 update of the WHO-EORTC classification. Presse Med. 2022;51(1):104126.
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229-1253.
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022;36(7):1720-1748.
van der Weyden CA, Pileri SA, Feldman AL, Whisstock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. Blood Cancer J. 2017;7(9):e603.
Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643-1649.
Bhatt G, Maddocks K, Christian B. CD30 and CD30-targeted therapies in Hodgkin lymphoma and other B cell lymphomas. Curr Hematol Malig Rep. 2016;11(6):480-491.
Gardner LJ, Polski JM, Evans HL, Perkins SL, Dunphy CH. CD30 expression in follicular lymphoma. Arch Pathol Lab Med. 2001;125(8):1036-1041.
Hao X, Wei X, Huang F, et al. The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. PLoS One. 2015;10(5):e0126615.
Hu S, Xu-Monette ZY, Balasubramanyam A, et al. CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study. Blood. 2013;121(14):2715-2724.
Mallipudi RM, Alquran L, Shenoy VA, Leslie LA, Conti JA. A rare case of grey zone lymphoma successfully treated with brentuximab vedotin and R-CHP chemotherapy. Case Rep Oncol Med. 2019;2019:4121234.
Piris M, Gatter KC, Mason DY. CD30 expression in follicular lymphoma. Histopathology. 1991;18(1):25-29.
Salas MQ, Climent F, Tapia G, et al. Clinicopathologic features and prognostic significance of CD30 expression in de novo diffuse large B-cell lymphoma (DLBCL): results in a homogeneous series from a single institution. Biomarkers. 2020;25(1):69-75.
Slack GW, Steidl C, Sehn LH, Gascoyne RD. CD30 expression in de novo diffuse large B-cell lymphoma: a population-based study from British Columbia. Br J Haematol. 2014;167(5):608-617.
Dilly M, Ben-Rejeb H, Vergier B, et al. Primary cutaneous follicle center lymphoma with Hodgkin and Reed-Sternberg-like cells: a new histopathologic variant. J Cutan Pathol. 2014;41(10):797-801.
Kampa F, Mitteldorf C. A review of CD30 expression in cutaneous neoplasms. J Cutan Pathol. 2021;48(4):495-510.
Aldarweesh FA, Treaba DO. Primary cutaneous follicle centre lymphoma with Hodgkin and Reed-Sternberg like cells: a case report and review of the literature. Case Rep Hematol. 2017;2017:9549428.
Asano H, Imai Y, Ota S, et al. CD30-positive anaplastic variant diffuse large B cell lymphoma: a rare case presented with cutaneous involvement. Int J Hematol. 2010;92:550-552.
Kempf W, Kazakov DV, Rutten A, et al. Primary cutaneous follicle center lymphoma with diffuse CD30 expression: a report of 4 cases of a rare variant. J Am Acad Dermatol. 2014;71:548-554.
Macgrogan G, Vergier B, Dubus P, et al. CD30-positive cutaneous large cell lymphomas. A comparative study of clinicopathologic and molecular features of 16 cases. Am J Clin Pathol. 1996;105:440-450.
Magro CM, Momtahen S. Primary cutaneous spindle cell B cell lymphoma: a report of three cases and review of the literature. Ann Diagn Pathol. 2017;27:18-23.
Magro CM, Nash JW, Werling RW, Porcu P, Crowson N. Primary cutaneous CD30+ large cell B-cell lymphoma: a series of 10 cases. Appl Immunohistochem Mol Morphol. 2006;14:7-11.
Oguz O, Engin B, Demirkesen C. Primary cutaneous CD30-positive large B-cell lymphoma associated with Epstein-Barr virus. Int J Dermatol. 2003;42:718-720.
Prieto-Torres L, Manso R, Cieza-Diaz DE, et al. Large cells with CD30 expression and Hodgkin-like features in primary cutaneous marginal zone B-cell lymphoma: a study of 13 cases. Am J Surg Pathol. 2019;43:1191-1202.
Servitje O, Gallardo F, Estrach T, et al. Primary cutaneous marginal zone B-cell lymphoma: a clinical, histopathological, immunophenotypic and molecular genetic study of 22 cases. Br J Dermatol. 2002;147:1147-1158.
Stein H, Mason DY, Gerdes J, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood. 1985;66:848-858.
Koens L, Senff NJ, Vermeer MH, Willemze R, Jansen PM. Methotrexate-associated B-cell lymphoproliferative disorders presenting in the skin: a clinicopathologic and immunophenotypical study of 10 cases. Am J Surg Pathol. 2014;38:999-1006.
Beylot-Barry M, Vergier B, Masquelier B, et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol. 1999;23:1208-1216.
Bourbon E, Maucort-Boulch D, Fontaine J, et al. Clinicopathological features and survival in EBV-positive diffuse large B-cell lymphoma not otherwise specified. Blood Adv. 2021;5:3227-3239.
Herrera E, Gallardo M, Bosch R, Cabra B, Aneri V, Sanchez P. Primary cutaneous CD30 (Ki-1)-positive non-anaplastic B-cell lymphoma. J Cutan Pathol. 2002;29:181-184.
Amitay-Laish I, Feinmesser M, Ben-Amitai D, et al. Juvenile onset of primary low-grade cutaneous B-cell lymphoma. Br J Dermatol. 2009;161:140-147.
Malysz J, Erdman P, Klapper J, Zhu J, Creer M, Bayerl MG. Clinical implications of CD30 expression in aggressive B-cell lymphomas. Clin Lymphoma Myeloma Leuk. 2016;16:429-433.
Gong QX, Lu TX, Liu C, et al. Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases. Int J Clin Exp Pathol. 2015;8:15825-15835.
Xu J, Oki Y, Saksena A, et al. CD30 expression and prognostic significance in R-EPOCH-treated patients with diffuse large B-cell lymphoma. Hum Pathol. 2017;60:160-166.
Gong QX, Wang Z, Liu C, et al. CD30 expression and its correlation with MYC and BCL2 in de novo diffuse large B-cell lymphoma. J Clin Pathol. 2018;71:795-801.
Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125:1394-1402.